Critics addressed the elephant in the room during the FDA’s first public meeting on trauma since its decision to delay ...

The FDA rejected MDMA-assisted therapy for PTSD. SetSet's April Pride calls for harm-reduction education and regulatory ...

The FDA rejected an application to approve MDMA, also known as ecstasy, as a treatment for PTSD. Next up among the ...

As Psychiatric Times reported, this decision puts on hold what could have been a landmark approval for the treatment of PTSD with MDMA, also known as midomafetamine. Despite the setback, Lykos ...

Efforts to make MDMA legally available as a psychotherapeutic catalyst hit a daunting roadblock in August. The Food and Drug ...

In a previous blog on the use of psychedelics to treat mental health disorders, we reported that the US Food and Drug ...

Delve into the psychedelic-assisted therapy market and investors' sentiment after the FDA's decision about Lykos' MDMA ...

Reuters.com is your online source for the latest news stories and current events, ensuring our readers up to date with any ...

Amy Emerson is stepping down on the heels of the FDA last month rejecting Lykos Therapeutics’ MDMA-based therapy for ...

The US Food and Drug Administration's (FDA) decision not to approve midomafetamine-assisted therapy (MDMA-AT) for posttraumatic stress disorder (PTSD) puts the therapy's near-term future in doubt ...

The Food and Drug Administration’s (FDA) recent rejection of midomafetamine (MDMA), along with mental health therapy, for the treatment of post-traumatic stress disorder (PTSD) came as no surprise.

The CEO's departure comes after Lykos co-founder and longtime psychedelic medicines advocate Rick Doblin stood down from the ...